News & Publications

In 2018, Governor Baker was joined by members of the Administration, Legislature and healthy aging community today at the ceremonial signing of H.4116 An Act relative to Alzheimer’s and related dementias in the Commonwealth during an event at the Alzheimer’s Association in Waltham. “Raising a…Read More

Key findings of a recent GE Healthcare Survey conducted with MillwardBrown indicate: 74% of respondents would want to know what kind of neurological disorder they had even if there was no cure 90% of respondents feel it is ‘fairly’ or ‘very’ important to have access to accurate diagnosis for…Read More

According to ScienceDaily, well-established research suggests extensive plaques and tangles in the brain result in the death of neurons and are an indicator of Alzheimer's dementia. But surprising new Northwestern Medicine research on the brains of individuals 90 years and older who had superior mem…Read More

2018 Alzheimer’s Disease Facts and Figures is a statistical resource for U.S. data related to Alzheimer’s disease, the most common cause of dementia. Background and context for interpreting the data are contained in the Overview. Additional sections address prevalence, mortality and morbidity, c…Read More

2019 Alzheimer’s Disease Facts and Figures is a statistical resource for U.S. data related to Alzheimer’s disease, the most common cause of dementia. Background and context for interpretation of the data are contained in the overview. Additional sections address prevalence, mortality and morbidi…Read More

In April 2015, The Milken Institute published a guide aimed at enhancing public understanding of the disease, and the current state of research and the current barriers to progress. Its further purpose is to outline ways in which philanthropy can advance a cure for AD, to trigger additional AD resea…Read More

We are proud to announce that our CEO, Paul Tanico, was recently interviewed by Global Business Reports to discuss the impacts of  our Discern™ Test which diagnoses Alzheimer's with unprecedented accuracy. The full article can be read here:   https://www.gbreports.com/interview/paul-tanico…Read More

The U.S. Food and Drug Administration has granted Breakthrough Device designation to DISCERN, a biomarker test for Alzheimer’s. The test was developed using blood and tissue samples that were monitored and evaluated by WVU’s Rockefeller Neurosciences Institute. If the test gains full approval,…Read More